< Back to search trials

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001/ENGOT-ov43)

  • Clinicaltrials.gov #: NCT03740165
  • Acronym: MK-7339-001 / KEYLYNK-001
  • Tumor Type: Gynecological
  • Tumor Subtype: Ovarian
  • Tumor Stage: N/A
  • Type of Treatment: